HIGHLIGHTS
- who: Alexander E. Perl from the (UNIVERSITY) have published the research: Clinical outcomes in patients with relapsed/refractory FLT3-mutated acute myeloid leukemia treated with gilteritinib who received prior midostaurin or sorafenib, in the Journal: (JOURNAL) of 10/Dec/2021
SUMMARY
Tyrosine kinase inhibitors (TKIs) that target the fms-like tyrosine kinase 3 (FLT3) receptor have demonstrated activity in patients with acute myeloid leukemia (AML) harboring activating mutations in FLT3, namely, FLT3 internal tandem duplications (FLT3ITD) in the juxtamembrane domain and FLT3 tyrosine kinase domain (FLT3-TKD) point mutations in the activation loop . . .
If you want to have access to all the content you need to log in!
Thanks :)
If you don't have an account, you can create one here.